Evidence map›Paper›PMID 39065732›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt.

Fadya M Elgarhy, Abdallah Borham, Noha Alziny, Khlood R AbdElaal, Mahmoud Shuaib, Abobaker Salem Musaibah, Mohamed Ali Hussein, Anwar Abdelnaser

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fadya M ElgarhyInstitute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.ORCID 0009-0003-3932-5558
Abdallah BorhamInstitute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.ORCID 0009-0008-9943-7961
Noha AlzinyInstitute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.ORCID 0009-0009-6751-6515
Khlood R AbdElaalGraduate Program of Biotechnology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.ORCID 0009-0009-0054-9283
Mahmoud ShuaibInstitute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.
Abobaker Salem MusaibahInstitute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.ORCID 0009-0008-1776-4636
Mohamed Ali HusseinInstitute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.ORCID 0000-0003-0349-7262
Anwar AbdelnaserInstitute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt.ORCID 0000-0003-0088-6799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenomics (PGx) is the hope for the full optimization of drug therapy while minimizing the accompanying adverse drug events that cost billions of dollars annually. Since years before the century, it has been known that inter-individual variations contribute to differences in specific drug responses. It is the bridge to what is well-known today as "personalized medicine". Addressing the drug's pharmacokinetics and pharmacodynamics is one of the features of this science, owing to patient characteristics that vary on so many occasions. Mainly in the liver parenchymal cells, intricate interactions between the drug molecules and enzymes family of so-called "Cytochrome P450" occur which hugely affects how the body will react to the drug in terms of metabolism, efficacy, and safety. Single nucleotide polymorphisms, once validated for a transparent and credible clinical utility, can be used to guide and ensure the succession of the pharmacotherapy plan. Novel tools of pharmacoeconomics science are utilized extensively to assess cost-effective pharmacogenes preceding the translation to the bedside. Drug development and discovery incorporate a drug-gene perspective and save more resources. Regulations and laws shaping the clinical PGx practice can be misconceived; however, these pre-/post approval processes ensure the product's safety and efficacy. National and international regulatory agencies seek guidance on maintaining conduct in PGx practice. In this patient-centric era, social and legal considerations manifest in a way that makes them unavoidable, involving patients and other stakeholders in a deliberate journey toward utmost patient well-being. In this comprehensive review, we contemporarily addressed the scientific leaps in PGx, along with various challenges that face the proper implementation of personalized medicine in Egypt. These informative insights were drawn to serve what the Egyptian population, in particular, would benefit from in terms of knowledge and know-how while maintaining the latest global trends. Moreover, this review is the first to discuss various modalities and challenges faced in Egypt regarding PGx, which we believe could be used as a pilot piece of literature for future studies locally, regionally, and internationally.

Indexed as

drug approvalpersonalized medicinePGxpharmacogenomicsregulatory

Identifiers

PMID39065732
PMCPMC11279872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.